drugset / Trial / NCT03004638
Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety pharmacokinetics, and pharmacodynamics of repeat weekly dosing of MEDI6012 in subjects with stable atherosclerosis.
Timeline
- Start
- 2017-01-23
- Primary completion
- 2017-11-02
- Completion
- 2017-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | recombinant human Lecithin Cholesterol Acyl Transferase | Protein / enzyme biologic | 40 mg | Intravenous |
| Subject | recombinant human Lecithin Cholesterol Acyl Transferase | Protein / enzyme biologic | 100 mg | Intravenous |
| Subject | recombinant human Lecithin Cholesterol Acyl Transferase | Protein / enzyme biologic | 120 mg | Intravenous |
| Subject | recombinant human Lecithin Cholesterol Acyl Transferase | Protein / enzyme biologic | 300 mg | Intravenous |